



4 February 2020

Company Announcements Office
Australian Securities Exchange
Exchange Centre
20 Bridge Street
Sydney, NSW 2000

Dear Sir/Madam

FORMAL LAUNCH OF THE NANABIS™ OBSERVATIONAL STUDY

- NanaBis™ Human Ethics approved Observational Study formally launches in Australia
- 125 Australian Doctors and 256 patients already enrolled
- Strong progression step in the company's overall drug registration pathway

Medlab Clinical Ltd (ASX: MDC) is pleased to announce it has formally launched the NanaBis™ Observational Study.

On 18 June 2019, MDC announced Ethics approval for the second NanaBis™ Study, the Human Ethics approved Observational Study (ACTRN # ACTRN12619000513112) to assess real world use of NanaBis™, by being able to provide further evidence, based on real world data for safety, tolerability, use and potential adverse events. In addition, the Study will help review the impact NanaBis™ has on the patient while being prescribed other prescriptive medicines.

The Study is assigned a Clinical Trial Number (CTN) by the TGA and all prescriptions are effectively being made under the Australian Government's Special Access Scheme (SAS).

This Study, in conjunction with the recently completed Phase 2 Cancer pain trial at Royal North Shore Hospital is part of Medlab's overall commitment to a clinical trials pathway to drug registration for NanaBis™. Medlab is currently developing a protocols for a Phase 3 trial to be used in Australia and USA.

The Study seeks to recruit 2,000 Australian patients via medical or hospital settings to provide intervention data over a 12-month period and is expected to provide for at least 700 patients diagnosed with cancer pain. The remaining patient group will be classified as suffering non-cancer pain. Patients will be offered NanaBis™ at a reduced price, thus reducing significantly the financial impact of the study. Doctors are also compensated for their time on a monthly per patient basis.

The recently announced commercial agreement with Tasmanian Alkaloids Pty Ltd allows Medlab to upscale manufacturing to cater for an increase in demand.

During the soft launch (required to test process) 125 Doctors were enrolled along with 256 patients, roughly 12% of the final anticipated cohort. Key points demonstrated are:

- 16% cancer pain
- 84% non-cancer pain
 - 28% soft tissue pain
 - 18% visceral pain
 - 38% muscular pain
 - 54% neuropathic pain

Medlab CEO, Dr Sean Hall said “Medlab will be working closely with healthcare professionals to provide educational tools to better understand NanaBis™ as a treatment option for patients living with chronic pain. Participating patients will have access to medical cannabis at a significantly reduced price.”

ABOUT NANABIS™

NanaBis™ is a standardised, purified 1:1 concentration of CBD and THC in MDC’s proprietary nanoparticle delivery platform, NanoCelle™. NanaBis™ is a drug candidate being investigated for use in cancer pain management with data to date very encouraging.

For and behalf of the Board.



Dr Sean Hall
Managing Director

ISSUED FOR: MEDLAB CLINICAL LTD (ASX: MDC) – www.medlab.co

FOR FURTHER INFORMATION: DR SEAN HALL, CEO, MEDLAB CLINICAL
TEL: +61 2 8203 9520, sean_hall@medlab.co

ABOUT MEDLAB – www.medlab.co

Medlab Clinical is an Australian based medical life science company, developing therapeutic pathways for diagnosed chronic diseases. It is advanced in developing therapies for pain management, depression and obesity as well as earning revenue from sale of nutritional products in Australia and the United States. In pain management Medlab is developing cannabis-based medicines. The Medlab developed nano-particle medicine delivery system, NanoCelle™, is being applied to its medicines, nutritional products and off-patent drugs like statins. Medlab has a growing patent portfolio.